(3-bromophenyl)(4-methoxyphenyl)methanol

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3-bromophenyl)(4-methoxyphenyl)methanol
• 英文别名: (3-bromophenyl)-(4-methoxyphenyl)methanol
• 化学式: C₁₄H₁₃BrO₂
• 分子量: 293.16
• InChiKey: GWEKPQSXQGUPRS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (3-bromophenyl)(4-methoxyphenyl)methanol 在 三乙基硅烷 、 三氟化硼乙醚 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 以92%的产率得到1-bromo-3-(4-methoxybenzyl)benzene
  参考文献：
  名称：

  C-Aryl 5a-carba-β-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes

  摘要：

  C-Aryl 5a-carba-beta-D-glucopyranose derivatives were synthesized and evaluated for inhibition activity against hSGLT1 and hSGLT2. Modifications to the substituents on the two benzene rings resulted in enhanced hSGLT2 inhibition activity and extremely high hSGLT2 selectivity versus SGLT1. Using the created superimposed model, the reason for the high hSGLT2 selectivity was speculated to be that additional substituents occupied a new space, in a different way than known inhibitors. Among the tested compounds, the ethoxy compound 5h with high hSGLT2 selectivity exhibited more potent and longer hypoglycemic action in db/db mice than our O-carbasugar compound (1) and sergliflozin (2), which could be explained by its improved PK profiles relative to those of the two compounds. These results indicated that 5h might be a promising drug candidate for the treatment of type 2 diabetes. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.04.053
• 作为产物：
  描述：

  3-溴-4'-甲氧基苯甲酮 在 sodium tetrahydroborate 作用下， 以 异丙醇 为溶剂， 生成 (3-bromophenyl)(4-methoxyphenyl)methanol
  参考文献：
  名称：

  Mindl,J.; Vecera,M., Collection of Czechoslovak Chemical Communications, 1972, vol. 37, p. 1143 - 1149

  摘要：

  DOI：

文献信息

• C-aryl glucoside SGLT2 inhibitors and method
  申请人：——

  公开号：US20030114390A1

  公开（公告）日：2003-06-19

  A method is provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of a compound of the formula 1 alone or in combination with one or more other antidiabetic agent(s) or other therapeutic agent(s).

  提供了一种用于治疗糖尿病及相关疾病的方法，使用化合物formula1的SGLT2抑制剂量，可以单独使用，也可以与一个或多个其他抗糖尿病药物或其他治疗药物组合使用。
• Halogen–Lithium Exchange of Sensitive (Hetero)aromatic Halides under Barbier Conditions in a Continuous Flow Set-Up
  作者：Niels Weidmann、Rodolfo H. V. Nishimura、Paul Knochel、Johannes H. Harenberg

  DOI：10.1055/s-0040-1707259

  日期：2021.2

  In memory of Prof. Dr. Kilian Muñiz Abstract A halogen–lithium exchange reaction of (hetero)aromatic halides performed in the presence of various electrophiles such as aldehydes, ketones, Weinreb amides, and imines using BuLi as exchange reagent and a commercially available flow set-up is reported. The organolithiums generated in situ were instantaneously trapped with various electrophiles (Barbier

  纪念KilianMuñiz教授 抽象 据报道，在各种亲电试剂（例如醛，酮，Weinreb酰胺和亚胺）的存在下，使用BuLi作为交换试剂，进行了（杂）芳族卤化物的卤素-锂交换反应，并使用了市售的流动装置。用各种亲电试剂（Barbier条件）瞬时捕获原位生成的有机锂，从而形成多官能（杂）芳烃。这种方法能够使含有高度敏感的官能团（如酯）的（杂）芳烃官能化，而这些官能团在间歇条件下是不能容忍的。 出版历史 收到：2020年7月21日 修订后接受：2020年7月29日 发布日期： 2020年9月2日（在线） ©2020年。Thieme。版权所有 Georg Thieme Verlag KGRüdigerstraße14，70469斯图加特，德国
• Scandium as a pre-catalyst for the deoxygenative allylation of benzylic alcohols
  作者：Ivan Šolić、Pattarakiat Seankongsuk、Joanna Kejun Loh、Tirayut Vilaivan、Roderick W. Bates

  DOI：10.1039/c7ob02219k

  日期：——

  pre-catalyst for the deoxygenative allylation of benzylic alcohols with a narrow substrate window. The reaction is shown to proceed through a “hidden Brønsted acid” mechanism. The reaction is efficient provided that the aryl group is neither too electron rich nor too electron poor. It is shown that this allows useful selectivity. The reaction also works for benzyhydryl alcohols with broader scope. The reaction

  三氟甲磺酸is是具有窄底物窗口的苯甲醇的脱氧烯丙基化的有效预催化剂。该反应显示为通过“隐藏的布朗斯台德酸”机理进行。只要芳基既不是太富电子又不是太贫电子，则该反应是有效的。结果表明，这允许有用的选择性。该反应也适用于范围更广的苯甲醇。该反应也可以由Nafion催化。
• [EN] C-ARYL GLUCOSIDE SGLT2 INHIBITORS<br/>[FR] INHIBITEURS DE SGLT2 A BASE DE GLUCOSIDE C-ARYLE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2001027128A1

  公开（公告）日：2001-04-19

  SGLT2 inhibiting compounds are provided having formula (I) where R?1, R2, and R2a¿ are independently hydrogen, OH, OR5, lower alkyl, CF¿3?, OCHF2, OCF3, SR?5i¿ or halogen, or two of R?1, R2 and R2a¿ together with the carbons to which they are attached can form an annelated five, six or seven membered carbocycle or heterocycle; R?3 and R4¿ are independently hydrogen, OH, OR5a, OAryl, OCH¿2?Aryl, lower alkyl, cycloalkyl, CF3, -OCHF2, -OCF3, halogen, -CN, -CO2R?5b, -CO¿2H, -COR6b, -CH(OH)R6c, -CH(OR?5h)R6d, -CONR6R6a¿, -NHCOR5c, -NHSO¿2R?5d, -NHSO¿2?Aryl, Aryl, -SR?5e, -SOR5f, SO¿2R5g, SO2Aryl, or a five, six or seven membered heterocycle, or R?3 and R4¿ together with the carbons to which they are attached form an annelated five, six or seven membered carbocycle or heterocycle; R?5, R5a, R5b, R5c, R5d, R5e, R5f, R5g, R5h, and R5I¿ are independently lower alkyl; R?6, R6a, R6b, R6c and R6d¿ are independently hydrogen, alkyl, aryl, alkylaryl or cycloalkyl, or R?6 and R6a¿ together with the nitrogen to which they are attached form an annelated five, six or seven membered heterocycle; A is O, S, NH, or (CH¿2?)n where n is 0 - 3. A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with another antidiabetic agent or other therapeutic agent.

  提供具有公式（I）的SGLT2抑制化合物，其中R?1，R2和R2a¿独立地是氢，OH，OR5，低碳基，CF¿3？，OCHF2，OCF3，SR?5i¿或卤素，或者R?1，R2和R2a¿中的两个与它们附着的碳可以形成一个嵌环的五元，六元或七元碳环或杂环；R?3和R4¿独立地是氢，OH，OR5a，OAryl，OCH¿2？Aryl，低碳基，环烷基，CF3，-OCHF2，-OCF3，卤素，-CN，-CO2R?5b，-CO¿2H，-COR6b，-CH（OH）R6c，-CH（OR?5h）R6d，-CONR6R6a¿，-NHCOR5c，-NHSO¿2R?5d，-NHSO¿2？Aryl，芳基，-SR?5e，-SOR5f，SO¿2R5g，SO2Aryl或五元，六元或七元杂环，或R?3和R4¿与它们附着的碳形成一个嵌环的五元，六元或七元碳环或杂环；R?5，R5a，R5b，R5c，R5d，R5e，R5f，R5g，R5h和R5I¿独立地是低碳基；R?6，R6a，R6b，R6c和R6d¿独立地是氢，烷基，芳基，烷基芳基或环烷基，或者R?6和R6a¿与它们附着的氮一起形成一个嵌环的五元，六元或七元杂环；A是O，S，NH或（CH¿2？）n，其中n为0-3。还提供了一种使用上述化合物的SGLT2抑制量单独或与另一种抗糖尿病药物或其他治疗药物组合治疗糖尿病和相关疾病的方法。
• C-ARYL GLUCOSIDE SGLT2 INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：EP1224195A1

  公开（公告）日：2002-07-24